Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose.

King CR, Porche-Sorbet RM, Gage BF, Ridker PM, Renaud Y, Phillips MS, Eby C.

Am J Clin Pathol. 2008 Jun;129(6):876-83. doi: 10.1309/1E34UAPR06PJ6HML.

PMID:
18480003
2.

Validation of clinical testing for warfarin sensitivity: comparison of CYP2C9-VKORC1 genotyping assays and warfarin-dosing algorithms.

Langley MR, Booker JK, Evans JP, McLeod HL, Weck KE.

J Mol Diagn. 2009 May;11(3):216-25. doi: 10.2353/jmoldx.2009.080123. Epub 2009 Mar 26.

3.

Comparison of performance of three commercial platforms for warfarin sensitivity genotyping.

Babic N, Haverfield EV, Burrus JA, Lozada A, Das S, Yeo KT.

Clin Chim Acta. 2009 Aug;406(1-2):143-7. doi: 10.1016/j.cca.2009.06.015. Epub 2009 Jun 21.

PMID:
19545555
4.

A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9.

Tham LS, Goh BC, Nafziger A, Guo JY, Wang LZ, Soong R, Lee SC.

Clin Pharmacol Ther. 2006 Oct;80(4):346-55.

PMID:
17015052
5.

Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations.

Wu AH, Wang P, Smith A, Haller C, Drake K, Linder M, Valdes R Jr.

Pharmacogenomics. 2008 Feb;9(2):169-78. doi: 10.2217/14622416.9.2.169.

PMID:
18370846
6.

Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians.

Borgiani P, Ciccacci C, Forte V, Romano S, Federici G, Novelli G.

Pharmacogenomics. 2007 Nov;8(11):1545-50.

PMID:
18034619
7.

Rapid single-nucleotide polymorphism detection of cytochrome P450 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genes for the warfarin dose adjustment by the SMart-amplification process version 2.

Aomori T, Yamamoto K, Oguchi-Katayama A, Kawai Y, Ishidao T, Mitani Y, Kogo Y, Lezhava A, Fujita Y, Obayashi K, Nakamura K, Kohnke H, Wadelius M, Ekström L, Skogastierna C, Rane A, Kurabayashi M, Murakami M, Cizdziel PE, Hayashizaki Y, Horiuchi R.

Clin Chem. 2009 Apr;55(4):804-12. doi: 10.1373/clinchem.2008.115295. Epub 2009 Jan 30.

8.

Prevalence of combinatorial CYP2C9 and VKORC1 genotypes in Puerto Ricans: implications for warfarin management in Hispanics.

Duconge J, Cadilla CL, Windemuth A, Kocherla M, Gorowski K, Seip RL, Bogaard K, Renta JY, Piovanetti P, D'Agostino D, Santiago-Borrero PJ, Ruaño G.

Ethn Dis. 2009 Autumn;19(4):390-5.

9.

Warfarin pharmacogenetics: does more accurate dosing benefit patients?

Eby C.

Semin Thromb Hemost. 2012 Oct;38(7):661-6. doi: 10.1055/s-0032-1326789. Epub 2012 Oct 9. Review.

10.

Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.

Kimura R, Miyashita K, Kokubo Y, Akaiwa Y, Otsubo R, Nagatsuka K, Otsuki T, Okayama A, Minematsu K, Naritomi H, Honda S, Tomoike H, Miyata T.

Thromb Res. 2007;120(2):181-6. Epub 2006 Oct 17.

PMID:
17049586
11.

Warfarin therapy: influence of pharmacogenetic and environmental factors on the anticoagulant response to warfarin.

Siguret V, Pautas E, Gouin-Thibault I.

Vitam Horm. 2008;78:247-64. doi: 10.1016/S0083-6729(07)00012-X. Review.

PMID:
18374198
12.

Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations.

Scott SA, Edelmann L, Kornreich R, Desnick RJ.

Am J Hum Genet. 2008 Feb;82(2):495-500. doi: 10.1016/j.ajhg.2007.10.002. Epub 2008 Jan 17.

13.

Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy.

Gong IY, Tirona RG, Schwarz UI, Crown N, Dresser GK, Larue S, Langlois N, Lazo-Langner A, Zou G, Roden DM, Stein CM, Rodger M, Carrier M, Forgie M, Wells PS, Kim RB.

Blood. 2011 Sep 15;118(11):3163-71. doi: 10.1182/blood-2011-03-345173. Epub 2011 Jul 1.

14.

[Association between CYP2C9 and VKORC1 genetic polymorphism and warfarin dose requirements].

Yang J, Miao LY, Huang CR, Shen ZY, Jiang WP.

Zhonghua Xin Xue Guan Bing Za Zhi. 2008 Feb;36(2):137-40. Chinese.

PMID:
19099951
15.

Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.

Yin T, Miyata T.

Thromb Res. 2007;120(1):1-10. Epub 2006 Dec 11. Review.

PMID:
17161452
16.

Factors influencing warfarin dose requirements in African-Americans.

Momary KM, Shapiro NL, Viana MA, Nutescu EA, Helgason CM, Cavallari LH.

Pharmacogenomics. 2007 Nov;8(11):1535-44.

PMID:
18034618
17.

Pharmacogenetic-based dosing of warfarin.

[No authors listed]

Med Lett Drugs Ther. 2008 May 19;50(1286):39-40. No abstract available.

PMID:
18487958
18.

Warfarin pharmacogenomics in children.

Vear SI, Stein CM, Ho RH.

Pediatr Blood Cancer. 2013 Sep;60(9):1402-7. doi: 10.1002/pbc.24592. Epub 2013 May 16.

19.

[Oral anticoagulation and pharmacogenetics: importance in the clinical setting].

Benusiglio PR, Desmeules J, de Moerloose P, Dayer P.

Rev Med Suisse. 2007 Sep 12;3(124):2030, 2033-4, 2036. Review. French.

PMID:
17955831
20.

SYBR Green-based real-time PCR assay for detection of VKORC1 and CYP2C9 polymorphisms that modulate warfarin dose requirement.

Huang SW, Li Q, Zhu SY, Li L, Xiong F, Jia YK, Xu XM.

Clin Chem Lab Med. 2009;47(1):26-31. doi: 10.1515/CCLM.2009.008.

PMID:
19117406

Supplemental Content

Support Center